Ultimately, this “pre-CAR-T” IFNγ exposure and subsequent Qa-1b induction may protect tumor cells from CAR-T therapy in vivo, a phenomenon that cannot be captured in vitro unless the in vivo environment is mimicked by pre-treating tumor cells with IFNγ. Here, IFNG is linked to neoplasm.